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ABSTRACT: Differences in conformational dynamics be-
tween two full-length monoclonal antibodies have been
probed in detail using Fast Photochemical Oxidation of
Proteins (FPOP) followed by proteolysis and LC-ESI-MS/
MS analyses. FPOP uses hydroxyl radical labeling to probe the
surface-accessible regions of proteins and has the advantage
that the resulting covalent modifications are irreversible, thus
permitting optimal downstream analysis. Despite the two
monoclonal antibodies (mAbs) differing by only three amino
acids in the heavy chain complementarity determining regions
(CDRs), one mAb, MEDI1912-WFL, has been shown to
undergo reversible self-association at high concentrations and
exhibited poor pharmacokinetic properties in vivo, properties which are markedly improved in the variant, MEDI1912-STT.
Identifying the differences in oxidative labeling between the two antibodies at residue level revealed long-range effects which
provide a key insight into their conformational differences. Specifically, the amino acid mutations in the CDR region of the
heavy chain resulted in significantly different labeling patterns at the interfaces of the CL−CH1 and CH1−CH2 domains, with the
nonaggregating variant undergoing up to four times more labeling in this region than the aggregation prone variant, thus
suggesting a change in the structure and orientation of the CL−CH1 interface. The wealth of FPOP and LC-MS data obtained
enabled the study of the LC elution properties of FPOP-oxidized peptides. Some oxidized amino acids, specifically histidine and
lysine, were noted to have unique effects on the retention time of the peptide, offering the promise of using such an analysis as
an aid to MS/MS in assigning oxidation sites.
Long-range conformational interactions between thevarious domains of monoclonal antibodies (mAbs),
particularly the variable (V) and constant (C) domains, has
been a hotly debated topic since the 1970s.1−3 Although
numerous studies have suggested a functional allosteric link
between antigen binding in the V domains of the antigen-
binding fragment (Fab) and C domain function in the
fragment crystallizable (Fc) region (reviewed in ref 2), the
prevailing hypothesis is that the Fab and Fc domains are
functionally independent,4,5 supported by the perceived
difficulty of transmitting allosteric conformational changes via
the highly flexible hinge connecting the two regions.6
However, recent mounting evidence suggests that long-range
conformational changes, either as a result of antigen binding or
amino acid substitutions, can be transmitted between C and V
domains within the Fab region of an antibody. It is now well-
established that class switches in the C domain of Fab arms can
affect antigen binding affinity7−10 and instigate changes in
cooperative unfolding.11 Further, class switches in either the C
or V domains can change the elbow angle of the Fab arm.7,12
Together these effects suggest that the conformation of the
antigen binding site can, to some extent, be modulated by
changes in the C domain, via long-range conformational
changes mediated via the elbow angle.9 Other studies
suggested that the reverse communication is also possible,
whereby antigen binding may change the conformation of the
C domains.13 Indeed, a systematic comparison of antigen-
bound and antigen-free mAb structures in the Protein Data
Bank (pdb) revealed conformational changes in the relative
orientation of V and C domains in the Fab for both heavy (H)
and light (L) chains, as well as significant movement of the
CH1−1 loop, an essential component of the CH1−CL
interface,14 suggesting that long-range conformational changes
within the Fab arm can be instigated from either direction.
Surprisingly, subtle changes, such as single amino acid
substitutions, have also been observed to cause long-range
conformational changes in Fabs. Individual point mutations at
the CL−VL interface have been shown to change thermal
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stability and antigen binding, as well as the hydrogen−
deuterium exchange (HDX) behavior, of the complementary-
determining regions (CDRs).15 More recently, Henderson et
al. demonstrated that a double mutation of amino acid side-
chains in the elbow and framework regions of the V domain
resulted in major increases in flexibility of the elbow joint and
in the more distant CDR loops of both the H and L chains.16
Robust analytical methods to characterize such long-range
conformational effects are crucial for our further understanding
of antibody function, and for the rational design of effective
biotherapeutics.
Fast photochemical oxidation of proteins (FPOP) is
emerging in the field of structural MS as a valuable method
with which to probe solvent accessibility and protein
structure.17−21 FPOP employs hydroxyl radicals, liberated
from photolysis of hydrogen peroxide, to covalently label
solvent-accessible amino acid side-chains (preferentially label-
ing aromatic or sulfur containing groups22), on the μs-ms time
scale.23−25 Following proteolysis and LC-MS/MS, the resulting
covalent oxidative modifications, the most common of which
are +16 Da, + 32 Da, and +14 Da, can be localized to residue-
level resolution using standard ergodic fragmentation techni-
ques, such as collision induced dissociation (CID).17 As such,
FPOP offers many advantages over alternative structural MS
techniques, such as hydrogen−deuterium exchange (HDX),
where single residue resolution is typically difficult to
achieve,26 and conditions required to minimize back exchange
of the reversible deuterium label limit the available analysis
time and choice of proteases for digestion.17
However, downstream analysis and interpretation of FPOP-
LC-MS/MS experimental data is highly complex. For example,
while the effects of sequence and nearby side-chains on the
degree of labeling are well-established in HDX-MS,27,28 these
aspects are currently less well-defined for FPOP experi-
ments.17,21 Similarly, FPOP analysis strategies to identify
modified residues currently rely solely on tandem MS, which
can be challenging given the inherent low abundance of most
oxidations and the multitude of isobaric products.29,30 Despite
this, FPOP has not only shown great promise with regards to
structural characterization of mAbs in epitope map-
ping,18,20,30−32 but has also been used to detect minor
conformational changes, distant to binding sites in both the
Fc33 and CDR regions,18 and recently has been used to identify
changes in solvent-accessible surface area of amyloid proteins
at subamino acid level resolution.17
Here, we explore the utility of FPOP to characterize MEDI-
1912, a human IgG1 mAb selected against nerve growth factor,
and its variant containing three amino acid substitutions in the
heavy chain CDRs: W30S, F31T, and L57T. Hereafter the
mAbs are referred to by their amino acid substitutions: WFL
(original variant) and STT (triple mutation variant).34
Although the introduction of the amino acid substitutions
resulted in no significant loss in antigen affinity (both have pM
Kd), STT showed a significantly reduced propensity to
undergo reversible self-association, had a 3-fold slower
clearance rate in vivo, and a reduced tendency for nonspecific
tissue association.34 The two variants respond differently under
stresses from shear and extensional flow35 and, although HDX
and cross-linking data suggested a possible interface for the
reversible self-association of WFL,34 the intramolecular
conformational changes associated with this triple mutation
have yet to be explored.
Using the extensive data sets generated by studying such
large proteins, we aimed to gain a better understanding of the
sensitivity and applicability of FPOP to probe long-range
conformational changes in mAbs, to appreciate the extent to
which our current understanding of the technique allows us to
interpret structural changes, and to determine the extent to
which trends in LC retention time can be used to aid MS/MS
in assigning oxidations at the residue level.
■ EXPERIMENTAL SECTION
Fast Photochemical Oxidation of Proteins (FPOP).
The FPOP experimental setup used was as described
previously.19 The mAb proteins, WFL and STT, were supplied
by AstraZeneca (Cambridge, UK) in formulation buffer (125
mM L-arginine in 20 mM sodium succinate buffer, pH 6.0).
Due to the radical scavenging effect of the arginine excipient,22
oxidation conditions were reoptimized from conditions
previously used in our group.17 Immediately prior to
irradiation, 3 μL of 5% v/v H2O2 was added to 100 μL of
solution containing the analyte protein at 0.1 mg mL−1,
concentrations at which both proteins have been shown to be
predominantly monomeric,34 in the formulation buffer
containing an additional 10 mM L-histidine scavenger.
Following irradiation, the sample was collected in an
Eppendorf vial containing 20 μL quench solution (100 mM
L-methionine, 1 μM catalase in the formulation buffer) and
placed immediately on ice. Control experiments under
identical conditions with the exception that the proteins
were not subjected to laser irradiation were carried out.
Protein Digestion. Disulfide bonds were reduced by
incubation with dithiothreitol (1 h, 65 °C, 500 rpm), before
alkylation with iodoacetamide (incubated in the dark for 45
min, 20 °C, 500 rpm) and trypsin digestion (1:50 w/w
enzyme/protein, incubated at 37 °C, for 18 h at 500 rpm).
ESI-MS Analyses. To verify that the intact proteins had
undergone photolytic oxidation, molecular masses were
determined using ESI-MS on a Xevo mass spectrometer
(Waters Corpn., Manchester, UK).
LC-MS/MS Analyses. Tryptic peptides (1 μL at 0.5 μM
peptide concentration) were injected onto a UPLC M-Class
nano-Acquity system equipped with a C18 column (75 μm ×
150 mm, Waters Corpn., Manchester, UK) and separated using
reverse-phase chromatography with a linear gradient of 1−60%
v/v MeCN in H2O (both containing 0.1% v/v formic acid)
over 90 min at 0.3 μL min−1. Peptides were analyzed using
ESI-MS/MS on an Orbitrap Fusion mass spectrometer
(ThermoFisher Scientific, Bremen, Germany) operating in
Orbitrap-iontrap mode (240 000 resolution, rapid) with the
following data dependent acquisition settings: TopN = 7,
maximum injection time = 200 ms, apex detection = on.
Dynamic exclusion was reduced to 3 s to allow MS/MS
fragmentation of isobaric FPOP modifications with similar
retention times.
Peptide Identification. Peptides were identified using
PEAKS X software (Bioinformatics Solutions Inc., Waterloo,
ON, Canada). Peptides were searched with a 10 ppm mass
error cut off and a false discovery rate of 0.1%. The following
oxidized mass additions were searched: +14 Da (CH2 to CO),
+16 Da (O), +32 Da (2O), +73 Da, and +89 Da (the latter
two being singly and doubly oxidized Cys following
carbamidomethylation). Quantification of modified peaks was
performed manually using Xcalibur software (ThermoFisher
Scientific, Bremen, Germany) by integration of peaks
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generated from extracted ion chromatograms (XICs) using the
following equation:
=
∑
+ ∑
%modified
modified
unmodifed modified
peak
allpeaks
All observed charge states were quantified for each peptide.
XICs were generated by extracting over the base peak of each
peptide isotope distribution, for each charge state. Unless
stated otherwise, residue level quantification data are combined
from all observed positional isomers for a single amino acid
residue. Where MS/MS was insufficient to localize the
modification to individual side-chains, the sequence of amino
acids to which the modification could be localized, are shown.
Modified peaks with retention times indistinguishable from
that of the unmodified peptide were excluded from
quantification as the possibility that these resulted from in-
source oxidations, rather than genuine FPOP modifications,
could not be ruled out. t tests were used to determine
statistically significant changes, where p < 0.01 was determined
to be statistically significant.
Structural Modeling of mAbs. Homology models of
both the Fab and Fc domains of full length WFL were
generated using SWISS-MODEL.36 The Fab homology model
was generated using pdb: 5wkz37 (sequence identity =
95.23%). The Fc homology model was generated using pdb:
5k6538 (sequence identity = 89.81%). These were then aligned
into the canonical ‘Y’ shape of an IgG using pdb: 1IGY.39
■ RESULTS AND DISCUSSION
Comparison of mAbs WFL and STT using FPOP LC-
MS/MS. The two mAbs, WFL and STT, were subjected
individually to photochemical oxidation using FPOP. In each
case, control experiments in which the protein was treated with
hydrogen peroxide but not exposed to laser irradiation were
carried out to ensure that only FPOP oxidation was assessed.
Following tryptic digestion of the oxidized and control
proteins, LC-ESI-MS/MS analysis of the resulting peptides
yielded 80% and 96% sequence coverage for WFL, and 82%
and 100% sequence coverage for STT, for the heavy and light
chains, respectively (Supporting Information (SI) Figures S1
and S2). Across both the heavy and light chains, 50 different
oxidized sites were identified (28 on the heavy chain, 22 on the
light chain), 45 of which were common to both WFL and STT.
The most obvious differences in identified modification sites
were directly proximal to the W30S and F31T mutations in the
heavy chain CDRs of the mAbs. The extracted ion chromato-
grams (XICs) for the modified and unmodified versions of the
WFL peptide covering residues 24−38 in this region (Figure
1a,b) show multiple modified species for both W30 and F31
eluting at different retention times. These isobaric oxidized
species, corresponding to the +16 Da incorporation of a single
oxygen atom, indicate multiple positional isomers resulting
from hydroxyl radical incorporation at different positions on
the aromatic rings of the tryptophan and phenylalanine side-
chains.17 Additionally, in some instances, W30 was found to
undergo two oxidations within the same side-chain resulting in
the overall addition of 32 Da.
Despite a prominent y ion series, commonly seen for tryptic
peptides40 (typically basic at their C terminus), for both WFL
and STT, several oxidized products were observed to have
ambiguous MS/MS data, localizing the modification to
between residues 35 and 37 (35-TWV-37) or to residues
W36 or V37 if water loss fragment ions are used for
assignment41 (Figure 1c). Owing to the significant reactivity
bias of side-chains in this remnant sequence, in addition to the
presence of multiple isobaric products, as well as double
oxidations, these modifications most likely arise from the
Figure 1. FPOP oxidations in the region surrounding the W30S and
F31T mutation sites. XICs for the unmodified (black), +16 Da
modified (red) and +32 Da doubly modified (purple) versions of each
peptide for (a) WFL (24-ASGGTFWFGAFTWVR-38) and (b) STT
(24-ASGGTFSTGAFTWVR-38). Peaks are annotated according to
which oxidized residue was identified using MS/MS. (c) Representa-
tive tandem MS spectra for unmodified (top) and modified (bottom
three) WFL peptides covering the region of WF substitutions. The
residue(s) in which the modification site was identified using MS/MS
are underlined, with the assigned modified residue highlighted in bold
on the sequence on each spectrum.
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oxidation of W36.22 Surprisingly, despite being a core residue
of the VH domain, this side-chain was ∼6-fold more labeled in
WFL than STT (Figure 2a), which suggests a notable change
in conformation and solvent accessibility of side-chains in this
region. Indeed, further examination of oxidized products in this
region lends weight to this hypothesis. F29 and F34, residues
either side of the mutation sites, are only observed to be
modified in the STT variant (Figure 1b). Similarly, F55,
present in the nearby VHCDR2 region and adjacent to the
mutation site L57, was observed to increase in labeling by ∼2-
fold in the STT variant (Figure 2a). Together, these findings
may suggest a structural rearrangement of the VH domain,
proximal to the heavy chain CDRs, in which all four of these
side-chains have altered solvent accessibility as a result of the
WFL-STT substitutions. However, recent evidence suggests
that side-chain microenvironment and amino acid sequence
can play a significant role in determining the degree to which
side-chains are susceptible to radical oxidation.17,21,42 The
W30S, F31T, and L57T substitutions are expected to decrease
the reactivity to hydroxyl radical labeling of these individual
amino acid positions by factors of 40, 13, and 3, respectively.22
This likely explains the absence of modification for two of the
equivalent amino acid positions in STT (S30 and T31; residue
57 labels in neither variant). Importantly, the substitution of
the FPOP reactive W30 and F31 side-chains for less oxidation-
prone residues may also explain the increased oxidation of the
nearby F55 and W36 side-chains in the STT variant, as well as
the oxidation of F29 and F34 seen solely in the STT variant,
which could be as a result of diminished competition for
hydroxyl radicals in the region. F29, F35, and F55 are all within
∼10 Å of the mutation site, hence hydroxyl radical attack on
nearby, less reactive/less solvent exposed groups in the region
could be expected to be more likely in STT. Recent reports
have suggested that hydrogen peroxide preferentially interacts
with certain side-chains, including threonine, but not leucine
residues.43,44 As such, an alternative explanation for the
increased modification on F55 in STT, is that the L57T
mutation increases the local concentration of hydrogen
peroxide. Although the effects of local microenvironment in
FPOP have not been fully explored, the local microenviron-
ment changes discussed here provide an alternative explanation
as the cause of the changes in oxidation observed in this region.
Four other modification sites, each with a p value <0.01,
showed a >4-fold difference in labeling between the two mAb
variants, all of which indicate significantly lower labeling in
WFL. These residues are P138 (unlabeled in WFL) and V136
in the CH1 domain (Figure 2a), in addition to W152 and an
unidentified modification between P186 and K190 (186-
PEQWK-190) in the CL domain (Figure 2b). Interestingly, all
four of these sites are found to occupy a region in the lower
half of the CL domain, at the CL−CH1 interface (Figure 3).
Minor oxidation changes between WFL and STT (<2-fold)
could also be localized to 286-FNW-288 (peptide 286-
FNWYVDGVEVHNAK-299) at the top of the nearby CH2
domain, again showing lower labeling in the WFL variant
(Figure 3). These oxidation differences between the WFL and
STT variants were surprising, as they are >60 Å from the
introduced mutations in the CDRs of the heavy chains of these
mAbs, and suggest either a conformational change of the
Figure 2. Quantification of oxidized sites of the mAbs WFL and STT. Sites of modification for WFL (red) and STT (blue) for (a) the heavy and
(b) the light chains are shown along the x axis. Modifications are localized to a residue, or short sequence of amino acids. Where the modification
could not be localized to a sequence of <6 amino acids, the first and last three residues in the sequence are highlighted. Mutation sites which were
found to be oxidized in either variant (W30S and F31T) are annotated with “M”. Inserts show low abundance modifications on rescaled axes. * = p
< 0.01; error bars show standard deviation (N = 3).
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constant domains, or a change in orientation of the CL−CH1
domains relative to one another.
Changes in the CL−CH1 interface thought to be related to
antigen binding have been reported elsewhere,14 suggesting a
conformational link between the two regions. One report
demonstrated that a class switch of the CL domain caused a
change in orientation of the CL−CH1 domains associated with
changes in CDR loop structure, which altered the surface
exposed hydrophobicity of that region.7 The data presented
here suggest a similar trend in reverse, whereby amino acid
substitutions that alter the surface-exposed hydrophobicity of
the CDRs elicit changes in CL−CH1 orientation. It has been
suggested that conformational changes between the C and V
domains of Fab arms occurs through the elbow angle between
the two domains.9 Although no modifications were identified
in the elbow region between the VH and CH1 domains in our
study, one modified species was identified in the elbow region
between the VL and CL domains, localized to P114/K115,
where ∼2.5-fold lower labeling was observed in WFL
compared with STT (p < 0.01, Figure 2b).
Perhaps the most striking difference in oxidative labeling was
observed for W152 in the light chain, located on the edge of
the CL domain (Figure 3). At the residue level, W152 showed
∼5-fold less oxidation for WFL than for STT (Figure 2b).
However, closer examination of the XIC revealed five distinct
peaks at different retention times, all corresponding to
modified W152, resulting from the incorporation of oxygen
at different positions on the side-chain, generating isobaric
positional isomers17,22 (Figure 4a). Previous studies have
shown that, in simpler systems, detailed examination and
quantification of individual tryptophan positional isomers in
FPOP can yield higher resolution structural information,
effectively offering subamino acid level resolution on changes
in protein structure for certain side-chains.17 Although no
robust method of fully characterizing positional isomers
following FPOP yet exists, and more work is needed to
establish the utility of these products in determining changes in
protein structure, separate quantification of the W152 isomers
observed here can provide some additional information on the
conformational changes for this side-chain.
Three of the four observed +16 Da isomers of W152 show
significantly lower labeling in WFL than in STT by up to
∼14×, indicative of a drastic change in the environment of this
side-chain between the two variants (Figure 4b). However, the
remaining +16 Da isomer, as well as the doubly oxidized +32
Da product, exhibit little change (Figure 4b). Given that the
relationship between changes in solvent accessibility and the
associated changes in modification for different side-chains has
yet to be established in FPOP, and is likely complicated by the
effects of the microenvironment discussed earlier, determining
the precise magnitude of the change in solvent accessibility for
W152 is challenging. However, the observation that some of
the W152 oxidation products are similar between the two
variants, could suggest that part of the W152 side-chain
remains buried in both WFL and STT. Relatedly, several
oxidized residues similarly proximal to the CL−CH1 interface
also show similar degrees of labeling between the two variants.
For example, F137 in the heavy chain, and W189 and K160 in
the light chain all show no statistically significant change,
Figure 2a and b). Together, these data could indicate a more
subtle rearrangement of the CL−CH1 interface, and highlight
the sensitivity of FPOP to identify minor conformational
changes and side-chain movements, which typically are difficult
to probe by lower resolution structural MS techniques, such as
HDX.
Insights from FPOP LC-MS/MS Retention Time Data.
Proteolytic digests, and subsequent LC-MS/MS data, from
Figure 3. Differences between WFL and STT following FPOP
oxidation. Significantly different modified sites (p < 0.01) are
indicated by spheres and colored by the magnitude of the difference
observed. The heavy and light chains are depicted by gray and green
ribbons, respectively. The mutations (W30S, F31T, L57T) are shown
as purple spheres. Insert: zoomed image of the CL−CH1, and CH1−
CH2 interfaces, where significant conformational changes were found
between WFL and STT. Oxidation sites are annotated in red letters
either to the residue level, or to a short sequence to which MS/MS
could localize the modification. Details of the WFL homology model
generated here can be found in SI Figure S3.
Figure 4. FPOP quantification of the light chain W152 positional
isomers. (a) XICs of the unmodified (black), +16 Da (red) and +32
Da (purple) modified peptide 134−153. Isobaric peaks 1−4 had a
single (+16 Da) oxidation; peak 5 had two oxidations (+32 Da). (b)
Quantification of the modified species, with the same peak 1−5
annotation as (a), for WFL (red) and STT (blue). Significantly
different modified sites (p < 0.01) are indicated with an *. Error bars
show standard deviation (N = 3).
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proteins oxidized by FPOP are complex, where multiple
different oxidized products, eluting at different retention times,
can be observed for each peptide, corresponding to different
oxidized residues within the peptide, as well as different
positional isomers of the same oxidized residue. Currently,
identification of the sites of FPOP oxidation is achieved by
interpretation of the MS/MS data, where LC separation prior
to MS is used primarily to separate peptides over time,
allowing more fragmentation spectra to be acquired, and
minimizing the occurrence of difficult to interpret, chimeric
tandem MS spectra, resulting from overlapping, or partially
separated, isobaric modified peptides. Although retention time
change for oxidized peptides is a well observed phenomenon,17
and optimal peptide separation prior to MS is, at present, an
essential requirement for adequate assignment and quantifica-
tion of oxidations in FPOP experiments, the LC separation
data has, to date, not been systematically investigated. Here, we
sought to explore the possibility that the LC separation data, in
conjunction with MS/MS, could be used as an aid in
identifying modified residues via trends in changes in retention
time for certain modified side-chains.
Retention time data were compiled from the most common
oxidative modifications identified unambiguously to the
residue level using MS/MS both from previous work in our
laboratory,17 as well as the data acquired in this study. This
allowed us to analyze the effects of different oxidative
modifications on the retention time of the peptide. Using
reverse-phase LC with an aqueous MeCN gradient, most
peptides with oxidative modifications were observed to elute at
lower MeCN concentrations (shorter retention times)
compared with their unmodified counterparts, as expected,
given the incorporoation of an oxygen atom and subsequent
decrease in hydrophobicity of the peptide. However, modified
peptides on which the oxidation was present on a histidine
side-chain were observed to elute reproducibly at higher
MeCN concentrations (later retention times) than their
unmodified peptide counterparts (Figure 5a), an observation
made previously by us and others17,32 but without further
details.
Histidine oxidation has previously been reported to render
protonation of the side-chain significantly less favorable, likely
due to the considerably lower proton affinity of the dominant
+16 Da oxidation product, 2-oxo-histidine (Figure 5b).22,45−47
This suggests the 2-oxo-histidine product is likely to remain
unprotonated under typical acidic LC conditions, likely
resulting in increased hydrophobicity of the modified peptide
compared to the unmodified version, despite the incorporation
of an oxygen atom and formation of a carbonyl group. This
hypothesis is supported by the observation that histidine
modifications, unlike modifications of other side-chains, can
show significant charge state bias toward lower charge states
(Figure 5b), although this bias was not observed in all cases
where histidine was the modified residue, and likely depends
on the presence of other protonatable groups on the peptide.
Similarly, we have found that oxidative modifications on lysine
residues have a reproducible effect on retention time, resulting
in peptide elution immediately prior to the unmodified species,
typically at an MeCN concentration 0.05−0.1% lower than the
unmodified peptide (Figure 5a). This is consistent with a
minimal effect of increased hydrophilicity on an already
hydrophilic side-chain. These observations highlight the
importance of quantifying all observable charge states when
analyzing FPOP data, and that the characteristics of oxidatively
labeled peptides can be used, along with MS/MS data, to
support the identification of modified residues.
We have also noted a number of instances in which some
oxidized peptides, with a range of modified residues identified
from tandem MS spectra, eluted with precisely the same
retention time as the unmodified peptide (SI Figure S4). One
feasible explanation for this is that low intensity modifications
of oxidation-prone side-chains may occur during the ESI
process, that is, after LC separation,48,49 accounting for the
identical retention times of a peptide in its unmodified and
modified forms. Although the prospect of oxidized and
unmodified versions of the same peptide eluting at the same
retention time cannot be ruled out, the possibility of these “in-
source” oxidations means that care should be taken when
interpreting such results, and further illustrates the importance
of utilizing the LC separation data when assigning FPOP
oxidations.
■ CONCLUSIONS
The results presented support the view that long-range
conformational changes can occur between the C and V
domains of the Fab region of antibodies, as evidenced by the
conformational changes observed, in our study, at the CL−CH1
interface, caused by the triple mutation in the heavy chain
Figure 5. Retention time analysis of FPOP oxidized peptides. (a)
Combined data analysis using retention time data from this study and
previous work in our laboratory17 identifies trends in the change in
retention time of the peptide in the presence of specific modifications.
The retention time of the unmodified peptide is set at 0. Histograms,
binned every Δ1% MeCN, are shown as shaded columns. Gaussian
fits of the raw data are shown as solid lines. Data used for this analysis
only include modifications that could be assigned unambiguously to
the residue level by MS/MS. (b) XICs for the unmodified (black),
and the 2+ and 3+ charge states (green and blue, respectively) of the
+16 Da modified peptide 313−328 from the heavy chain of the mAbs.
Annotations above each peak show which side-chain was modified, as
determined by MS/MS.
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CDRs. Previous studies using FPOP and other hydroxyl radical
foot printing methods have observed long-range changes in
oxidative labeling as a result of binding to both the CDRs18
and the Fc regions.33 These data, and those presented here,
highlight the sensitivity of FPOP to identify minor conforma-
tional or side-chain solvent accessibility changes that could be
vital in protein allostery and protein−protein interactions.
However, the magnitude of the conformational rearrangement
observed at the CL−CH1 interface here cannot reliably be
determined from these data. While several side-chains in the
region show >4 fold difference in labeling, other nearby groups
show no change between the two variants. Interpretation of
FPOP data in this regard would benefit greatly from increased
understanding of the relationship between solvent accessible
surface area and the degree of modification observed, as well as
the effects of microenvironment17,21 and the effect these
factors have on the observed positional isomers.17 Similarly,
the significance of these conformational differences with
regards to the poor pharmacological properties of WFL cannot
be established from these data. However, it has been noted
recently that for light chain dimers, structurally similar to the
Fab domains in antibodies,50 the CL domains modulate
aggregation of the full length protein, whereas the interface
between the constant domains was suggested as a potential
target for preventing aggregation in light chain amyloidosis.51
Therefore, it seems plausible that the conformational differ-
ences we observe between the WFL and STT mAbs at the
interface between the CL−CH1 domains of the Fab may
contribute to the propensity of WFL to form aggregates, and
undergo reversible self-association.34,35
The retention time analysis of oxidized peptides in this study
also reveals the potential for using the LC separation as a
supportive analysis tool in identifying oxidized residues.
Although fragmentation spectra are undoubtedly the gold
standard in identifying FPOP oxidations, retention time
prediction of peptides in reverse-phase LC has long been
established,52 and the data presented here demonstrate the
possibility of establishing a similar analysis to aid in identifying
oxidation sites in FPOP. Further, positional isomers of
oxidized aromatic residues have been shown to elute with a
predictable retention time order using reverse-phase chromato-
graphic separation, both in short peptides and as free amino
acids.53,54 As such, retention time analysis and prediction could
be a useful future tool for characterizing positional isomers in
FPOP experiments.
The utility of FPOP as a method of probing protein
structure and dynamics has now been demonstrated with
regards to epitope mapping in biotherapeutics18,20,30−32 and
the structural characterization of other systems aggregation
prone protein proteins17 and studies into protein folding.19,55
Although more work is needed to advance FPOP further, both
in method development, and in data analysis and interpreta-
tion,56 the sensitivity to conformational changes demonstrated
here illustrate that FPOP can be a powerful analytical probe in
the structural MS toolbox.
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